Although high-dose aflibercept provides anatomical improvements, such as reductions in macular fluid, it does not significantly alter visual acuity over the course of treatment, according to a study.
The study included 219 eyes from both treatment-naïve patients and those previously treated with anti-VEGF agents.
High-dose aflibercept led to significant reductions in subretinal and intraretinal fluid (P = 0.006 and P = 0.002, respectively), best-corrected visual acuity remained stable, with no significant changes from baseline to the final visit (P = 0.934). Although the mean treatment interval extended from 5.8 to 7.4 weeks in previously treated patients (P < 0.0001), nearly half of the eyes (46.6%) with intervals shorter than 8 weeks continued to exhibit persistent macular fluid.
These findings highlight both the potential and the limitations of high-dose aflibercept in managing chronic nAMD in real-world settings.
Reference
Bala S, Barbosa GCS, Mohan N, et al. Initial Functional and Anatomical Outcomes of High-Dose Aflibercept 8 mg in Exudative Neovascular Age-Related Macular Degeneration. Ophthalmol Retina. 2025;S2468-6530(25)00054-5. doi: 10.1016/j.oret.2025.02.002. Epub ahead of print. PMID: 39923899.
Related Content
